1. D. Baker (2004) ‘Financing Drug Research: What Are the Issues?’ Center for Economic and Policy Research, (available at
http://www.cepr.net
/documents/publications/intellectual_property_2004_09.pdf, accessed April 14th 2008).
2. E. Berndt, R. Glennerster, M. Kremer, J. Lee, R. Levine, G. Weizsacker, and H. Williams (2007) ‘Advance Market Commitments for Vaccines Against Neglected Diseases: Estimating Costs and Effectiveness,’ Health Economics, 16: 491–511.
3. Center for Global Development (CGD) (2005) Making Markets for Vaccines: Ideas to Action. (Washington, DC: Center for Global Development), (available at
http://www.cgdev.org
/doc/books/vaccine/Making-Markets-complete.pdf, accessed April 14, 2008).
4. P. Chirac, and E. Torreele (2006) ‘Global Framework on Essential Health R&D,’ The Lancet, 367: 1560–1561.
5. P. Danzon, and A. Towse (2003) ‘Differential Pricing for Pharmaceuticals: Reconciling Access, R&D and Patents,’ International Journal of Health Care Finance and Economics, 3: 183–205.